Efficacy and Safety of Tocilizumab for TAO

• Status: Withdrawn
• Trial end date: 2023-09-23
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the efficacy and safety of tocilizumab treating Thyroid Associated Ophthalmopathy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University

Criteria

Inclusion criteria:

Age 18-70 years old

• Clinical diagnosis of Thyroid-associated ophthalmopathy

• Euthyroid status at least 1 months before baseline.

• No previous specific therapy for TAO, except for local measures

• Written informed consent is obtained

Exclusion criteria:

• Uncontrolled diabetes or hypertension

• Renal or hepatic insufficiency.

• Infectious diseases (HIV, HBV,TB and so on)

• History of mental/psychiatric disorder

• Other ocular diseases or fundus diseases.

• Any previous systemic medications or surgery for the treatment of TAO

• Pregnant or lactating females.

• Intolerability of tocilizumab